Harmony Biosciences Holdings
$ 38.13
-0.94%
26 Dec - close price
- Market Cap 2,196,149,000 USD
- Current Price $ 38.13
- High / Low $ 38.52 / 37.94
- Stock P/E 12.03
- Book Value 14.50
- EPS 3.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.26 %
- 52 Week High 40.93
- 52 Week Low 25.52
About
Harmony Biosciences Holdings, Inc. is a pioneering pharmaceutical company located in Plymouth Meeting, Pennsylvania, dedicated to developing innovative therapies for rare neurological disorders, particularly narcolepsy. The company is well-positioned in the specialty pharmaceuticals market, leveraging a strong product pipeline and advanced R&D capabilities to tackle significant unmet medical needs in the neurology sector. By focusing on rare diseases, Harmony aims to deliver substantial growth while significantly improving patient quality of life, thereby reinforcing its role as a critical player in the advancement of healthcare solutions.
Analyst Target Price
$46.18
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-27 | 2025-08-05 | 2025-04-28 | 2025-02-20 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-22 | 2023-10-31 | 2023-08-01 | 2023-05-02 | 2023-02-21 |
| Reported EPS | 1.08 | 0.92 | 0.7785 | 1.08 | 0.79 | 0.2 | 0.67 | 0.45 | 0.75 | 0.56 | 0.66 | 0.79 |
| Estimated EPS | 0.8149 | 0.72 | 0.9136 | 0.8171 | 0.67 | -0.06 | 0.6 | 0.48 | 0.65 | 0.63 | 0.47 | 0.58 |
| Surprise | 0.2651 | 0.2 | -0.1351 | 0.2629 | 0.12 | 0.26 | 0.07 | -0.03 | 0.1 | -0.07 | 0.19 | 0.21 |
| Surprise Percentage | 32.5316% | 27.7778% | -14.7877% | 32.1748% | 17.9104% | 433.3333% | 11.6667% | -6.25% | 15.3846% | -11.1111% | 40.4255% | 36.2069% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRMY
2025-12-28 12:10:50
Paradiem LLC recently acquired 26,279 shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) for approximately $724,000, contributing to the company's high institutional ownership of 86.23%. While Harmony Biosciences missed Q3 EPS estimates, its revenue surpassed expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $45.63. Insiders also own 23.6% of the stock, with recent insider selling activity noted.
2025-12-27 09:09:26
Exchange Traded Concepts LLC significantly increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 102.6% in the third quarter, acquiring an additional 32,923 shares. This brings their total holdings to 65,023 shares, valued at approximately $1.79 million. The article also notes that CEO Jeffrey M. Dayno sold a substantial number of shares, and analysts maintain a "Moderate Buy" consensus rating with a target price of $45.63 for HRMY.
2025-12-18 16:09:36
Harmony Biosciences (NASDAQ:HRMY) saw its stock price drop by 3.9% after CEO Jeffrey M. Dayno sold 25,933 shares for over $1 million. The stock traded at $37.2550, with trading volume significantly below average. Despite the drop, analysts maintain a "Moderate Buy" consensus rating with a target price of $45.63, though individual targets vary.
2025-12-18 03:10:27
Jeffrey M. Dayno, President and CEO of Harmony Biosciences Holdings and a 10% owner, sold 25,933 shares of common stock for $1,040,102 on December 12, 2025. This transaction, executed under a Rule 10b5-1 trading plan, leaves Dayno with no direct ownership in the company's common stock. The sale price was a weighted average of $40.1073 per share.
2025-12-18 03:10:27
Harmony Biosciences Holdings, Inc. CEO and Director, Jeffrey M. Dayno, executed a stock option for 20,000 shares at $8.22 per share on December 12, 2025. On the same day, he sold a total of 25,933 shares in open-market transactions, priced between $40.00 and $40.28, under a Rule 10b5-1 trading plan. Following these transactions, the CEO beneficially owns 0 shares of common stock directly from this option grant.
2025-12-17 23:11:09
Harmony Biosciences CEO Jeffrey Dayno sold 25,933 shares of the company's stock on December 12th for over $1 million. The stock traded down $0.05 to $38.78 on Wednesday, while market capitalization stands at $2.23 billion with a P/E ratio of 12.20. Despite missing Q3 EPS estimates, the company's revenue beat expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $45.63.
